Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 3, 2007, Pages 778-786

  Horrillo, Raquel ^a   Planagumà, Anna ^a   González Périz, Ana ^a   Ferré, Natàlia ^a   Titos, Esther ^a   Miquel, Rosa ^a   López Parra, Marta ^a   Masferrer, Jaime L ^b   Arroyo, Vicente ^a   Clària, Joan ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 4 [3 [4 (2 METHYLIMIDAZOL 1 YL)PHENYLTHIO]]PHENYL 3,4,5,6 TETRAHYDRO 2H PYRAN 4 CARBOXAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ARACHIDONIC ACID; CARBON TETRACHLORIDE; CJ 13610; CYCLOOXYGENASE 2 INHIBITOR; DOCEBENONE; INTERLEUKIN 6; LEUKOTRIENE B4; LICOFELONE; LIPOXYGENASE INHIBITOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HEPATITIS; LIVER FIBROSIS; LIVER PROTECTION; MACROPHAGE; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANIMALS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CARBON TETRACHLORIDE; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS, TOXIC; IMIDAZOLES; IN SITU NICK-END LABELING; LIPOXYGENASE INHIBITORS; LIVER CIRRHOSIS, EXPERIMENTAL; MACROPHAGES; MALE; MICE; MICE, INBRED STRAINS; OXIDATION-REDUCTION; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFIDES; SULFONAMIDES;

EID: 36348999868     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.128264     Document Type: Article

References (44)

1. Barrios-Rodiles M, Tiraloche G, and Chadee K (1999) Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1β and TNF-α. J Immunol 163:963-969.
2. Celotti F and Durand T (2003) The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat 71:147-162.
3. 2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res 23:185-195.
4. Cheng J, Imanishi H, Liu W, Iwasaki A, Ueki N, Nakamura H, and Hada T (2002b) Inhibition of the expression of α-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun 297:1128-1134.
5. Decker K (1990) Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 192:245-261.
6. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, and Iredale JP (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56-65.
7. Efsen E, Bonacchi A, Pastacaldi S, Valente AJ, Wenzel UO, Tosti-Guerra C, Pinzani M, Laffi G, Abboud HE, Gentilini P, et al. (2001) Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology 33:713-721.
8. 2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a cholinedeficient, L-amino acid-defined diet in rats. Carcinogenesis 17:467-475.
9. Fischer L, Steinhilber D, and Werz O (2004) Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 142:861-868.
10. FitzGerald GA and Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
11. Friedman SL and Bansal MB (2006) Reversal of hepatic fibrosis - fact or fantasy? Hepatology 43:S82-S88.
12. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871-1875.
13. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, and Cui J (2004) Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24:1783-1788.
14. Iredale JP, Benyon RC, McCullen PM, Northrop M, Pawley S, Hovell C, and Arthur MJ (1998) Mechanisms of spontaneous resolution of rat liver fibrosis. J Clin Invest 102:538-549.
15. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, and Milas L (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitior. Cancer Res 60:1326-1331.
16. Kouzan S, Brody AR, Nettesheim P, and Eling T (1985) Production of arachidonic acid metabolites by macrophages exposed in vitro to asbestos, carbonyl iron particles, or calcium ionophore. Am Rev Respir Dis 131:624-632.
17. Laufer SA, Augustin J, Dannhardt G, and Kiefer W (1994) (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 37:1894-1897.
18. López-Parra M, Clària J, Titos E, Planagumà A, Parrizas M, Masferrer JL, Jiménez W, Arroyo V, Rivera F, and Rodés J (2005) The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ: Influence of albumin. J Hepatol 42:75-81.
19. Marcouiller P, Pelletier JP, Guevremont M, Martel-Pelletier J, Ranger P, Laufer S, and Reboul P (2005) Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1β synthesis. J Rheumatol 32:704-712.
20. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, and Gentilini P (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152:423-430.
21. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacladi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, et al. (2000) Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119:466-478.
22. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, and Gentilini P (1999) Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29:140-148.
23. Martel-Pelletier J, Lajeunesse D, Reboul P, and Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62:501-509.
24. McClain CJ, Barve S, Deaciuc I, Kugelmas M, and Hill D (1999) Cytokines in alcoholic liver disease. Semin Liver Dis 19:205-219.
25. Mohammed NA, El Aleem SA, El Hafiz HA, and McMahon RF (2004) Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 57:350-354.
26. Muller WA (2001) New mechanisms and pathways for monocyte recruitment. J Exp Med 194:F47-F51.
27. Nanji AA, Miao L, Thomas P, Rahemtulla A, Khwaja S, Zhao A, Khwaja S, Tahan SR, and Dannenberg AJ (1997) Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatology 26:1538-1545.
28. Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, López-Cabrera M, Boscá L, Clemente G, García-Monzón C, et al. (2004) Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 53:1665-1672.
29. Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, and Rodés J (2005) The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARγ activation. FASEB J 19:1120-1122.
30. Reding T, Bimmler D, Perren A, Sun L-K, Fortunato F, Storni F, and Graf R (2006) A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut 55:1165-1173.
31. Romano M and Clària J (2003) Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J 17:1986-1995.
32. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, and Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171-1176.
33. Sipe JD, Bartle LM, and Loose LD (1992) Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response. J Immunol 148:480-484.
34. Titos E, Clària J, Bataller R, Bosch-Marcé M, Ginès P, Jiménez W, Arroyo V, Rivera F, and Rodés J (2000) Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 119:794-805.
35. Titos E, Clària J, Planagumà A, López-Parra M, González-Périz A, Gaya J, Miquel R, Arroyo V, and Rodés J (2005) Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol 78:871-874.
36. Titos E, Clària J, Planagumà A, López-Parra M, Villamor N, Párrizas M, Carrió A, Miquel R, Jiménez W, Arroyo V, et al. (2003) Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J 17:1745-1747.
37. Tries S, Neupert W, and Laufer S (2002) The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51:135-143.
38. Uemura M, Buchholz U, Kojima H, Kepper A, Hafkemeyer P, Fukui H, Tsujii T, and Keppler D (1994) Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology 20:804-812.
39. Vane JR and Botting RM (1998) Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47:S78-87.
40. Vidal C, Gómez-Hernández A, Sánchez-Galán E, González A, Ortega L, Gómez-Gerique JA, Tunon J, and Egido J (2007) Licofelone, a balanced inhibitor or cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 320:108-116.
41. Wallace JL, Carter J, McKinght W, Tries S, and Laufer SA (1994) ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 271:525-531.
42. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, et al. (2003) JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 125:556-571.
43. Yu J, Hui AY, Chu ES, Cheng AS, Go MY, Chan HL, Leung WK, Cheung KF, Ching AK, Chui YL, et al. (2007) Expression of a Cox-2 transgene in murine liver causes hepatitis. Gut 56:991-999.
44. Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, Hall P, Kirsch R, Leclercq I, and Farell GC (2006) COX-2 induction in mice with experimental nutritional steatohepatitis: role as proinflammatory mediator. Hepatology 43:826-836.